Targeting PLOD2 suppresses invasion and metastatic potential in radiorecurrent prostate cancer
Together, our results demonstrate for the first time the role of PLOD2 in radiorecurrent prostate cancer invasiveness, and point towards its potential as a therapeutic target to reduce metastasis and improve survival outcomes in prostate cancer patients.
Authors
- Roni Haas (ORCID: https://orcid.org/0000-0003-1505-2965)
- Paul C. Boutros (ORCID: https://orcid.org/0000-0003-0553-7520)
- Stanley K. Liu (ORCID: https://orcid.org/0000-0001-6851-0857)
- Thomas Kislinger (ORCID: https://orcid.org/0000-0003-3525-5540)
- Jessica Wright (ORCID: https://orcid.org/0000-0002-2731-7804)
- Hon S. Leong (ORCID: https://orcid.org/0000-0001-7801-1402)
- Urban Emmenegger (ORCID: https://orcid.org/0000-0002-3178-1896)
- Gavin Frame (ORCID: https://orcid.org/0009-0004-2924-134X)
- Xiaoyong Huang (ORCID: https://orcid.org/0000-0002-5946-4737)
- Michelle R. Downes (ORCID: https://orcid.org/0000-0002-4528-3724)
Institutions
- Sunnybrook Health Science Centre (CA)
- University Health Network (CA)
- University of California, Los Angeles (US)
- University of Toronto (CA)
- Health Sciences Centre (CA)
- Princess Margaret Cancer Centre (CA)
- Sunnybrook Research Institute
Publication Details
- Journal
- BJC Reports
- Published
- 2024-08-21
- DOI
- https://doi.org/10.1038/s44276-024-00085-3
- Citations
- 6
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.51
Funders
- Prostate Cancer Foundation
- Movember Foundation
- Prostate Cancer Canada
- University of Toronto
- Instituto Tecnológico de Costa Rica
- National Institutes of Health
- Canadian Institutes of Health Research